Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls
Open Access
- 9 June 2023
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (2) , 303-315
Abstract
Regulators and Health Technology Assessment (HTA) bodies are increasingly familiar with, and publishing guidance on, external controls derived from real‐world data (RWD) to generate real‐world evidence (RWE). We recently conducted a systematic literature review (SLR) evaluating publicly available information on the use of RWD‐derived external controls to contextualize outcomes from uncontrolled trials submitted to the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and/or select HTA bodies. The review identified several key operational and methodological aspects for which more detailed guidance and alignment within and between regulatory agencies and HTA bodies is necessary. This paper builds on the SLR findings by delineating a set of key takeaways for the responsible generation of fit‐for‐purpose RWE. Practical methodological and operational guidelines for designing, conducting, and reporting RWD‐derived external control studies are explored and discussed. These considerations include: (i) early engagement with regulators and HTA bodies during the study planning phase; (ii) consideration of the appropriateness and comparability of external controls across multiple dimensions, including eligibility criteria, temporality, population representation, and clinical evaluation; (iii) ensuring adequate sample sizes, including hypothesis testing considerations; (iv) implementation of a clear and transparent strategy for assessing and addressing data quality, including data missingness across trials and RWD; (v) selection of comparable and meaningful endpoints that are operationalized and analyzed using appropriate analytic methods; and (vi) conduct of sensitivity analyses to assess the robustness of findings in the context of uncertainty and sources of potential bias.Keywords
This publication has 42 references indexed in Scilit:
- Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for EuropeClinical Pharmacology & Therapeutics, 2019
- Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and OpportunitiesTherapeutic Innovation & Regulatory Science, 2018
- Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision makingPharmacoepidemiology and Drug Safety, 2017
- Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design ElementsJNCI: Journal of the National Cancer Institute, 2017
- Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesAnnals of Oncology, 2016
- Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and ElaborationAnnals of Internal Medicine, 2015
- Principled missing data methods for researchersSpringerPlus, 2013
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco LitigationHealth Services and Outcomes Research Methodology, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986